Descriptive characteristics of the sample. by Ronna Bañada (19233063)

Subjects:

<i>hdc</i> silencing results in cellular stress in the hematopoietic niche. by Bayan Kharrat (19959505)

Comparing detector performance against increasing signal to noise ratios. by Bernd Porr (32394)

<i>hdc</i> silencing causes cell death and cell cycle arrest in the PSC. by Bayan Kharrat (19959505)

Linear covariate analysis of prognostically significant metabolites. Presenting the effect sizes of metabolites that showed significant differences among prognostic groups in ICU-treated COVID-19 patients. Metabolites were included based on an F-value > 2.5 and a p-value < 0.05. Metabolites marked with a single asterisk (*) were significant in both two-way ANOVA and ASCA, whereas those marked with double asterisks (**) were significant only in two-way ANOVA. Positive effect sizes indicate an increase in metabolite concentration between the compared groups, while negative values indicate a decrease. by Emir Matpan (21655811)

“…Positive effect sizes indicate an increase in metabolite concentration between the compared groups, while negative values indicate a decrease.…”

The mean number of the emerged <i>D. melanogaster</i> adults. Mean number (±SE) of emerged adults and average percentage (±SE) of the residual fertility at the different treatment... by Flavia Cerasti (21655934)

<i>Aedes aegypti</i> database from SAGO traps. by Jesús A. Aguilar-Durán (9931967)

Subjects:

A) RT-qPCR analysis of <i>Yap</i>, <i>Taz</i>, and <i>Tead2</i> shows a significant decrease in transcript levels over postnatal stages from P0 to P28. by Heather L. Dingwall (14573796)

Difference in by Akihiro Kakimoto (343218)

Subjects:

Experimental protocol. by Akihiro Kakimoto (343218)

Subjects:

Relationship between the change in by Akihiro Kakimoto (343218)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

Subjects:

Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

Subjects: